Non-Small Cell Lung Cancer Market Industry Share, Growth,
Segments and Forecast - 2031

The global non-small cell lung cancer market is growing at a
CAGR of 9.6% during the forecast period (2024-2031). NSCLC is a type of cancer
that is most common among smokers as well as non-smokers group of people. NSCLC
in comparison to the other form of cancer called small cell lung cancer grows
and spreads less aggressively. Therefore, NSCLC has a better chance of
treatment with surgery, chemotherapy, and other medical treatments. The major
factor propelling the growth of the NSCLC market includes evolving drug
landscape for the treatment of NSCLC. The major factors that are augmenting the
growth of the market are the rise in air pollution, smoking cigarettes, pipes,
or cigars, being in exposure to asbestos, arsenic, chromium, beryllium, nickel,
soot, or tar in the workplace, and being exposed to radiation. Around 84% of
the tumor is non-small cell lung cancer and most of the advanced stage is
treated with chemotherapy, targeted drugs, and/or immunotherapy. 

Get Free Sample link @ https://www.omrglobal.com/request-sample/non-small-cell-lung-cancer-market

In addition to this, hereditary causes and being infected
with HIV are another factor that drives the global non-small cell lung cancer
diagnostics and therapeutics market. However, the high cost of drugs and
treatment and the risk associated with it are some of the restraints that can
challenge the growth of the market in the forecast period. Conversely rise in
better chances of treatment with surgery, chemotherapy, and other medical
treatments are estimated to be the opportunity for the market players. Moreover,
the significant increase in the R&D activities supported by government
organizations such as the American Lung Association, which has made support for
lung cancer research its top priority, is also aiding with the growth of the
market. 

Full report of Non-Small Cell Lung Cancer Market available @ https://www.omrglobal.com/industry-reports/non-small-cell-lung-cancer-market

Impact of COVID-19 on the Global Non-Small Cell Lung
Cancer Market

The global non-small lung cancer market is hardly hit by the
COVID-19 pandemic since December 2019. Key industry therapy of non-small cell
lung cancer includes chemotherapy, radiation therapy, surgery, and targeted
therapy in top economies such as China, the US, and European Union. The
COVID-19 pandemic in these major economies has led to delay in treatment across
the globe. Moreover, the frequent visits to hospitals might considerably
increase the risk of being infected due to which many patients themselves
decided to delay the treatment. During the global pandemic, the 30-day
mortality rate in patients with newly diagnosed NSCLC significantly increased
with the pandemic from 25% before COVID-19 to 49% during COVID-19. However, the
market will witness “W” shape recovery in near future owing to the increase in
the number of patients who experienced a delay in treatment in major economies.
The market will show a decline in share twice due to the most economies faced
by the second wave. One of the growth opportunities includes the clinical
guideline published by the National Institute for Health and Care Excellence
(NICE) for the guidance of standard anticancer treatments to cancer patients
with COVID-19 and to maximize the use of the available resources to sustain
health services. 

Segmental Outlook 

The market is segmented based on type, therapy, diagnosis,
and end-user. Based on the type segment, the market is segmented into
adenocarcinomas, squamous cell carcinoma, large cell carcinomas, and others.
Based on the therapy segment, the market is segmented into chemotherapy,
targeted therapy, radiation therapy, surgery, cryosurgery, and others. Among
these, the chemotherapy segment is anticipated to have significantly large
shares during the forecast period. Based on the diagnosis segment, the market
is segmented into CT scan, x-rays, sputum cytology, bronchoscopy, laboratory
tests, thoracoscopy, and others. Further based on the end-user segment, the
market is bifurcated into multispeciality hospitals and cancer research
centers. 

Reasons to Buying From us -



1. We cover more than 15 major industries, further segmented into more than 90
sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after
purchasing your report.

For
More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/non-small-cell-lung-cancer-market

Media Contact:



Contact Person: Mr. Anurag Tiwari

Email: anurag@omrglobal.com

Contact no: +91 780-304-0404

Company Name: Orion Market Research



About Orion Market Research



Orion Market Research (OMR) is a market research and consulting company known
for its crisp and concise reports. The company is equipped with an experienced
team of analysts and consultants. OMR offers quality syndicated research
reports, customized research reports, consulting and other research-based
services. The company also offers Digital Marketing services through its
subsidiary OMR Digital and Software development and Consulting Services through
another subsidiary Encanto Technologies.